razoxane has been researched along with Neoplasms in 80 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 32 (40.00) | 18.7374 |
1990's | 22 (27.50) | 18.2507 |
2000's | 18 (22.50) | 29.6817 |
2010's | 7 (8.75) | 24.3611 |
2020's | 1 (1.25) | 2.80 |
Authors | Studies |
---|---|
Armenian, SH; de Baat, EC; Feijen, EAM; Kremer, LCM; Mavinkurve-Groothuis, AMC; Mulder, RL; van Dalen, EC | 1 |
Cohen, GI; Emami, B; Gradishar, WJ; Green, DM; Hagerty, KL; Hensley, ML; Kewalramani, T; Meropol, NJ; Mitchell, RB; Schuchter, LM; Thigpen, JT; Trotti, A; von Hoff, D; Wasserman, TH | 1 |
Jones, RL | 1 |
Ahn, HS; Choi, HS; Choi, JY; Kang, HJ; Noh, CI; Park, ES; Shin, HY; Yun, YS | 1 |
Dervisis, NG; FitzPatrick, WM; Kitchell, BE | 1 |
Caron, HN; Kremer, LC; Raphaël, MF; van Dalen, EC; van den Berg, H | 1 |
Caron, HN; Dickinson, HO; Kremer, LC; van Dalen, EC | 1 |
De Grève, J; Fontaine, C; Noens, L; Pierre, P | 1 |
Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL | 1 |
Kang, M; Kim, KI; Oh, JM; Shin, WG; Song, YC | 1 |
Gisterek, I; Mazur, G; Wróbel, T; Włodarska, I; Zymliński, R; Łacko, A | 1 |
Hellmann, K | 5 |
Komagata, H; Sakai, H | 1 |
Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y | 1 |
Champion, C; Durand, JB; Ewer, MS; Gibbs, H; Lenihan, DJ; Swafford, J; Tong, AT; Yeh, ET; Yusuf, SW; Zafarmand, AA | 1 |
Gershanovich, ML | 1 |
Anderson, B | 1 |
Cvetković, RS; Scott, LJ | 1 |
Blazek, B; Elbl, L; Hrstkova, H; Michalek, J; Tomaskova, I | 1 |
Kik, K; Szmigiero, L | 1 |
Alvarez, JA; Barry, E; Lipshultz, SE; Miller, TL; Scully, RE | 1 |
Hasinoff, BB; Herman, EH | 1 |
Hogle, WP | 1 |
Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
Liu, TF; Zhang, XF; Zhang, ZY | 2 |
Belt, R; Haas, C; Hoogstraten, B; Liesmann, J | 1 |
Bruno, S; Macdonald, JS; Penta, JS; Poster, DS | 1 |
Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL | 1 |
Davis, HL; Earhart, RH; Koeller, JM; Robins, HI; Rodriguez, R; Tormey, DC; Tutsch, KD; Vogel, CL | 1 |
Bruno, S; Macdonald, JS; Marsoni, S; Penta, J; Poster, DS | 1 |
Giraldi, T; Sava, G | 1 |
Bamberg, M; Holfeld, H | 1 |
Baker, D; Constable, W; Elkon, D; Rinehart, L | 1 |
Hochster, H; Speyer, J; Wasserheit, C | 1 |
Armand, JP; de Forni, M | 1 |
Lewis, C | 1 |
Hale, JP; Lewis, IJ | 1 |
Bu'Lock, FA; Gabriel, HM; Martin, RP; Mott, MG; Oakhill, A | 1 |
Basser, RL; Cebon, J; Duggan, G; Green, MD; Mihaly, G; Rosenthal, MA; Sobol, MM | 1 |
Catimel, G; Clavel, M; Merrouche, Y | 1 |
Furue, H | 1 |
Lipshultz, SE | 1 |
Trotti, A | 1 |
Mott, MG | 1 |
Spencer, CM; Wiseman, LR | 1 |
Brion, N; Paule, B | 1 |
Bramwell, V; Moran, LA; Seymour, L | 1 |
Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP | 1 |
Chow, W; Doroshow, JH; Gandara, D; Groshen, S; Johnson, K; Lenz, HJ; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Yen, Y | 1 |
Field, EO; Hellmann, K | 1 |
Hensley, ML; Meropol, NJ; Schuchter, LM; Winer, EP | 1 |
Alford, DA; Allen, LM; Creaven, PJ | 1 |
Carter, SK; Slavik, M | 2 |
Hellmann, K; Hill, BT | 1 |
Hagemann, G; Töllner, D | 1 |
Cavalli, F | 1 |
Boggust, WA; McGauley, H | 1 |
Carter, WH; Crews, SL; Howells, R; Wampler, GL | 1 |
Cangir, A; Dyment, PG; Komp, DM; Land, VJ; Sexauer, CL; Starling, KA | 1 |
Catalano, RB; Engstrom, PF; Paul, AR | 1 |
Bakowski, MT | 1 |
Duke, DI | 1 |
Carlson, RW | 1 |
Blum, RH; Downey, A; Goldenberg, A; Oratz, R; Speyer, JL; Walsh, C | 1 |
Kamen, B; Krischer, JP; Vats, T | 1 |
Hellmann, K; Rhomberg, W | 1 |
Dorr, RT | 1 |
Hammershaimb, LD; Hurson, SB; Marsoni, S; Simon, RM; Ungerleider, RS | 1 |
Earhart, RH; Glaubiger, DL; Gribble, TJ; Holcenberg, JS; Kamen, BA; Pratt, CB; Tutsch, KD; Ungerleider, RS | 1 |
Agarwal, RP; Davila, E; Eisenberger, M; Gorowski, E; Kosinski, J; Savaraj, N; Vogel, CL | 1 |
Wideröe, R | 1 |
32 review(s) available for razoxane and Neoplasms
Article | Year |
---|---|
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Topics: Aged; Animals; Anthracyclines; Antibiotics, Antineoplastic; Bone Marrow; Cardiotonic Agents; Chelating Agents; Child; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heart Diseases; Humans; Neoplasms; Razoxane | 2008 |
Cardioprotective interventions for cancer patients receiving anthracyclines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cytoprotection; Heart Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane | 2011 |
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antioxidants; Carbazoles; Cardiolipins; Cardiotonic Agents; Carvedilol; Doxorubicin; Erythropoietin; Heart; Heart Diseases; Humans; Lipid Peroxidation; Liposomes; Neoplasms; Piperazines; Propanolamines; Purines; Razoxane; Risk Factors; Sildenafil Citrate; Sulfones; Survivors; Ventricular Dysfunction, Left | 2012 |
[Cardiac toxicity in cancer therapy].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathy, Dilated; Cardiovascular Agents; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Radiotherapy, Adjuvant; Razoxane; Risk Factors; Sarcoma | 2002 |
Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Razoxane | 2003 |
[Chemotherapy-induced cardiac toxicity and management].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography; Heart; Heart Diseases; Humans; Monitoring, Physiologic; Neoplasms; Razoxane | 2003 |
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
Topics: Anthracyclines; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Cardiovascular Diseases; Cytokines; Heart; Humans; Neoplasms; Pericardium; Radiation Injuries; Radiotherapy; Razoxane; Risk Factors | 2004 |
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Humans; Neoplasms; Razoxane | 2005 |
Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane | 2005 |
[Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Neoplasms; Razoxane | 2006 |
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Drug Interactions; Drug Monitoring; Heart; Heart Diseases; Humans; Neoplasms; Razoxane; Risk Factors | 2007 |
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Topics: Animals; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Enzyme Inhibitors; Heart Diseases; Humans; Neoplasms; Prodrugs; Razoxane; Topoisomerase II Inhibitors | 2007 |
Cytoprotective agents used in the treatment of patients with cancer.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Fibroblast Growth Factors; Glutamine; Humans; Mesna; Neoplasms; Razoxane | 2007 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interferons; Medroxyprogesterone; Medroxyprogesterone Acetate; Methyltestosterone; Neoplasms; Phosphonoacetic Acid; Razoxane; Tamoxifen; Teniposide; Vinca Alkaloids | 1982 |
ICRF-187 in clinical oncology.
Topics: Animals; Antineoplastic Agents; Dogs; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Piperazines; Razoxane | 1981 |
Selective antimetastatic drugs (review).
Topics: Animals; Antineoplastic Agents; Hemostasis; Humans; Leukemia; Leukemia, Experimental; Mice; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Protease Inhibitors; Rats; Razoxane | 1981 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors | 1995 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane | 1994 |
A review of the use of chemoprotectants in cancer chemotherapy.
Topics: Adrenocorticotropic Hormone; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Humans; Mesna; Neoplasms; Peptide Fragments; Razoxane | 1994 |
Anthracyclines: cardiotoxicity and its prevention.
Topics: Antibiotics, Antineoplastic; Child; Child, Preschool; Drug Administration Schedule; Heart; Humans; Neoplasms; Razoxane; Risk Factors | 1994 |
Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Kidney Diseases; Neoplasms; Neutropenia; Razoxane | 1993 |
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Topics: Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Neoplasms; Razoxane; Treatment Outcome | 1996 |
Toxicity antagonists in cancer therapy.
Topics: Amifostine; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Growth Substances; Humans; Mesna; Neoplasms; Palliative Care; Radiotherapy; Razoxane; Superoxide Dismutase | 1997 |
Anthracycline cardiotoxicity and its prevention.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Heart; Humans; Infant; Neoplasms; Razoxane | 1997 |
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Heart Diseases; Humans; Neoplasms; Razoxane | 1998 |
[Anticancer chemotherapy. Prevention of complications].
Topics: Antidotes; Antineoplastic Agents; Dose-Response Relationship, Drug; Glutathione; Heart; Humans; Iron Chelating Agents; Mesna; Neoplasms; Protective Agents; Razoxane; Vomiting | 1998 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Chromomycins; Cisplatin; DNA, Neoplasm; Drug Evaluation, Preclinical; Etoposide; Humans; Ifosfamide; Leukemia L1210; Mice; Mitosis; National Institutes of Health (U.S.); Neoplasms; Neoplasms, Experimental; Razoxane; Tegafur; Teniposide; United States | 1976 |
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Guanazole; Humans; Ifosfamide; Male; National Institutes of Health (U.S.); Neoplasms; Nitrogen Mustard Compounds; Nitrosourea Compounds; Razoxane; United States | 1977 |
[New substances in oncologic therapy].
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin | 1978 |
Radiotherapeutic enhancement by razoxane.
Topics: Animals; Combined Modality Therapy; Female; Humans; Male; Mice; Neoplasm Metastasis; Neoplasms; Radiation-Sensitizing Agents; Razoxane | 1991 |
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluorouracil; Humans; Ifosfamide; Leucovorin; Mesna; Methotrexate; Neoplasms; Razoxane; Sulfhydryl Compounds; Uridine | 1991 |
12 trial(s) available for razoxane and Neoplasms
Article | Year |
---|---|
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Male; Neoplasms; Razoxane; Ventricular Function, Left | 2010 |
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Razoxane; Sarcoma; Sepsis; Treatment Outcome | 2004 |
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Blood Pressure; Body Mass Index; Cardiovascular Agents; Child; Child, Preschool; Czech Republic; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography, Stress; Female; Follow-Up Studies; Heart; Heart Rate; Humans; Infant; Male; Neoplasms; Prospective Studies; Razoxane; Time Factors; Treatment Outcome | 2005 |
Preliminary report on AT1727 as a potential radiosensitizer.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasms; Piperazines; Radiation-Sensitizing Agents; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1984 |
Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Interactions; Head and Neck Neoplasms; Humans; Lymphoma; Mice; Neoplasm Metastasis; Neoplasms; Piperazines; Razoxane | 1980 |
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Heart; Heart Diseases; Humans; Neoplasms; Pilot Projects; Razoxane | 1993 |
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Topics: Adult; Aged; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Razoxane; Stomatitis; Vomiting | 1994 |
Anthracycline cardiotoxicity and its prevention.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Heart; Humans; Infant; Neoplasms; Razoxane | 1997 |
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cations; Chromatography, High Pressure Liquid; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Razoxane; Time Factors | 2001 |
Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.
Topics: Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Neoplasms; Razoxane | 1992 |
Phase II trial of ICRF-187 in children with solid tumors and acute leukemia.
Topics: Acute Disease; Adolescent; Child; Drug Evaluation; Humans; Leukemia; Neoplasms; Razoxane | 1991 |
ADR-529 (ICRF-187).
Topics: Clinical Trials as Topic; Humans; Neoplasms; Piperazines; Razoxane | 1989 |
37 other study(ies) available for razoxane and Neoplasms
Article | Year |
---|---|
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms; Polyketides; Razoxane | 2023 |
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Topics: Amifostine; Antineoplastic Agents; Fibroblast Growth Factor 7; Humans; Mesna; Neoplasms; Practice Guidelines as Topic; Radiation-Protective Agents; Razoxane | 2009 |
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
Topics: Animals; Cardiovascular Agents; Dog Diseases; Dogs; Doxorubicin; Drug Therapy, Combination; Gastrointestinal Diseases; Heart Diseases; Neoplasms; Razoxane | 2010 |
Should anthracyclines and dexrazoxane be used for children with cancer?
Topics: Anthracyclines; Antineoplastic Agents; Child; Heart; Humans; Neoplasms; Neoplasms, Second Primary; Razoxane | 2011 |
Savene® (dexrazoxane) use in clinical practice.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Belgium; Catheterization, Central Venous; Chelating Agents; Data Collection; Debridement; Extravasation of Diagnostic and Therapeutic Materials; Humans; Neoplasms; Razoxane; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2012 |
Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
Topics: Adolescent; Age Factors; Anthracyclines; Cardiovascular Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Heart Function Tests; Hospitals, Teaching; Humans; Infant; Male; Neoplasms; Razoxane; Republic of Korea; Retrospective Studies | 2012 |
[Cardioxan: prevention of anthracycline-related cardiotoxicity].
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cardiotonic Agents; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasms; Neoplasms, Experimental; Razoxane; Time Factors | 2004 |
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Hodgkin Disease; Humans; Neoplasms; Razoxane; Research Design; Risk; Risk Factors | 2007 |
Phase II evaluation of AT-1727 in advanced human cancer.
Topics: Antineoplastic Agents; Drug Evaluation; Humans; Neoplasms; Piperazines; Razoxane | 1983 |
Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Granulocytes; Humans; Infusions, Parenteral; Leukocyte Count; Leukopenia; Myeloproliferative Disorders; Neoplasms; Piperazines; Platelet Count; Razoxane | 1981 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide | 1982 |
Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients.
Topics: Blood Proteins; Chromatography, High Pressure Liquid; Humans; Infusions, Parenteral; Kinetics; Neoplasms; Piperazines; Razoxane; Stereoisomerism | 1982 |
[General principles and new trends of cytostatic tumor therapy].
Topics: Antineoplastic Agents; Cisplatin; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Neoplasms; Nitrosourea Compounds; Podophyllotoxin; Radiation-Sensitizing Agents; Razoxane | 1980 |
The influence of ICRF-159 and levamisole on the incidence of metastases following local irradiation of a solid tumor.
Topics: Animals; Female; Levamisole; Mice; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Radiation-Induced; Piperazines; Radiotherapy; Radiotherapy Dosage; Razoxane; Risk | 1981 |
Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane | 1996 |
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
Topics: Adult; Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane | 1996 |
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome | 1999 |
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 1999 |
Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Drug Screening Assays, Antitumor; Mammals; Neoplasms; Razoxane; Time Factors; Tumor Cells, Cultured | 1970 |
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Topics: Amifostine; Antineoplastic Agents; Chelating Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 2002 |
The bioavailability in man of ICRF-159 a new oral antineoplastic agent.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Feces; Humans; Middle Aged; Neoplasms; Piperazines; Razoxane; Time Factors | 1975 |
Razoxane and methotrexate resistance.
Topics: Cell Line; Cell Survival; Drug Resistance; Humans; Lymphocytes; Methotrexate; Neoplasms; Piperazines; Razoxane | 1977 |
[The effect of bleomycin, ICRF 159 and of simultaneous X-ray application on CHO-fibroblasts].
Topics: Animals; Bleomycin; Cell Survival; Drug Therapy, Combination; Neoplasms; Piperazines; Razoxane | 1977 |
Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy.
Topics: Antineoplastic Agents; Aprotinin; Collagen; Cyclophosphamide; Edetic Acid; Fluorouracil; HeLa Cells; Humans; Microbial Collagenase; Neoplasms; Phenanthrolines; Razoxane; Thiotepa | 1978 |
On determining the levels of treatment to optimize the probability of a favorable response.
Topics: Altretamine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Leukemia L1210; Mice; Mice, Inbred Strains; Models, Biological; Neoplasms; Razoxane; Statistics as Topic | 1977 |
ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
Topics: Adolescent; Child; Drug Administration Schedule; Drug Evaluation; Hematopoiesis; Humans; Neoplasms; Piperazines; Razoxane | 1979 |
Razoxane - a new anti-tumour agent.
Topics: Humans; Neoplasms; Piperazines; Razoxane | 1978 |
Radiosensitizers.
Topics: Animals; Cell Survival; Humans; In Vitro Techniques; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Razoxane | 1978 |
Phase I trial of ICRF-159 in combination with 1.3 bis-(2-chloroethyl)-1-nitrosourea (MeCCNU).
Topics: Bone Marrow; Drug Evaluation; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Neoplasms; Piperazines; Razoxane; Semustine | 1978 |
ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
Topics: Animals; Antineoplastic Agents; Cricetinae; Dogs; Drug Synergism; Haplorhini; Humans; Immunosuppressive Agents; Leukemia; Neoplasm Metastasis; Neoplasms; Piperazines; Rabbits; Radiation-Sensitizing Agents; Rats; Razoxane; Teratogens | 1976 |
Prenatal effects of the cancer chemotherapeutic drug ICRF 159 in mice, rats, and rabbits.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Female; Fetus; Gestational Age; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Neoplasms; Piperazines; Pregnancy; Rabbits; Rats; Razoxane | 1975 |
Reducing the cardiotoxicity of the anthracyclines.
Topics: Antibiotics, Antineoplastic; Biopsy, Needle; Endocardium; Heart Diseases; Heart Failure; Heart Function Tests; Humans; Myocardium; Neoplasms; Razoxane; Risk Factors; Sensitivity and Specificity | 1992 |
Tolerance to antineoplastic agents in children and adults.
Topics: Adult; Ancitabine; Antineoplastic Agents; Child; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Humans; Hypotension; Leukemia; Lymphoma; Neoplasms; Posture; Razoxane; Retrospective Studies | 1985 |
ICRF-187 and razoxane in cancer treatment.
Topics: Female; Humans; Neoplasms; Piperazines; Razoxane | 1987 |
Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.
Topics: Adolescent; Adult; Blood Coagulation Tests; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Enzymes; Half-Life; Hematologic Diseases; Humans; Kinetics; Neoplasms; Piperazines; Razoxane; Stereoisomerism; Tissue Distribution | 1986 |
Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperazines; Razoxane | 1987 |
Optimization of cancer radiotherapy with selective sensitizers.
Topics: Cells, Cultured; Chemical Phenomena; Chemistry; Combined Modality Therapy; Humans; Metronidazole; Misonidazole; Neoplasms; Oxygen Consumption; Radiation Dosage; Radiation-Sensitizing Agents; Razoxane | 1987 |